Olipharma, a small nucleic acid drug Contract Development and Manufacturing Organization (CDMO) based in Suzhou, has reportedly raised an undisclosed amount of money in a Pre-Series A+ financing round. The investment was led by Tsing Song Capital and Addor Capital, with participation from existing investor Matrix Partners. The proceeds will be used to construct manufacturing facilities.
Company Overview and Services
Founded in 2021, Olipharma offers a comprehensive range of “one-stop” CDMO services for small nucleic acid drugs. These services include drug design and screening, laboratory research and development, process and analysis development, CMC services, API production, and drug registration. The company is equipped with four core technology platforms: a nucleic acid solid phase synthesis platform, a chemical modification and coupling platform, a process development and analysis platform, and a CMC pharmaceutical research platform.
Significance of the Financing
The Pre-Series A+ financing round provides Olipharma with the necessary capital to expand its manufacturing capabilities and enhance its service offerings. This expansion will enable the company to better meet the growing demand for small nucleic acid drugs and strengthen its position as a leading CDMO in the industry.-Fineline Info & Tech
